182 related articles for article (PubMed ID: 35697379)
1. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity.
Thier B; Zhao F; Stupia S; Brüggemann A; Koch J; Schulze N; Horn S; Coch C; Hartmann G; Sucker A; Schadendorf D; Paschen A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35697379
[TBL] [Abstract][Full Text] [Related]
2. RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation.
Engel C; Brügmann G; Lambing S; Mühlenbeck LH; Marx S; Hagen C; Horváth D; Goldeck M; Ludwig J; Herzner AM; Drijfhout JW; Wenzel D; Coch C; Tüting T; Schlee M; Hornung V; Hartmann G; Van den Boorn JG
Cancer Immunol Res; 2017 Jun; 5(6):455-467. PubMed ID: 28468914
[TBL] [Abstract][Full Text] [Related]
3. Melanoma Differentiation Trajectories Determine Sensitivity toward Pre-Existing CD8
Harbers FN; Thier B; Stupia S; Zhu S; Schwamborn M; Peller V; Chauvistré H; Crivello P; Fleischhauer K; Roesch A; Sucker A; Schadendorf D; Chen Y; Paschen A; Zhao F
J Invest Dermatol; 2021 Oct; 141(10):2480-2489. PubMed ID: 33798535
[TBL] [Abstract][Full Text] [Related]
4. NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
Perotti V; Baldassari P; Molla A; Vegetti C; Bersani I; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2016 Jun; 35(22):2862-72. PubMed ID: 26387540
[TBL] [Abstract][Full Text] [Related]
5. Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy.
Jacobson ME; Wang-Bishop L; Becker KW; Wilson JT
Biomater Sci; 2019 Jan; 7(2):547-559. PubMed ID: 30379158
[TBL] [Abstract][Full Text] [Related]
6. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
Such L; Zhao F; Liu D; Thier B; Le-Trilling VTK; Sucker A; Coch C; Pieper N; Howe S; Bhat H; Kalkavan H; Ritter C; Brinkhaus R; Ugurel S; Köster J; Seifert U; Dittmer U; Schuler M; Lang KS; Kufer TA; Hartmann G; Becker JC; Horn S; Ferrone S; Liu D; Van Allen EM; Schadendorf D; Griewank K; Trilling M; Paschen A
J Clin Invest; 2020 Aug; 130(8):4266-4281. PubMed ID: 32427578
[TBL] [Abstract][Full Text] [Related]
7. Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.
Elion DL; Jacobson ME; Hicks DJ; Rahman B; Sanchez V; Gonzales-Ericsson PI; Fedorova O; Pyle AM; Wilson JT; Cook RS
Cancer Res; 2018 Nov; 78(21):6183-6195. PubMed ID: 30224377
[TBL] [Abstract][Full Text] [Related]
8. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
[TBL] [Abstract][Full Text] [Related]
9. Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.
Daßler-Plenker J; Paschen A; Putschli B; Rattay S; Schmitz S; Goldeck M; Bartok E; Hartmann G; Coch C
Int J Cancer; 2019 Apr; 144(7):1645-1656. PubMed ID: 30230526
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma.
Li Y; Song Y; Li P; Li M; Wang H; Xu T; Yu X; Yu Y; Tai Y; Chen P; Cai X; Wang X; Xiang L; Deng R; Zhang X; Gao L; Wang X; Liu J; Cao F
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152220
[TBL] [Abstract][Full Text] [Related]
11. Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy.
Helms MW; Jahn-Hofmann K; Gnerlich F; Metz-Weidmann C; Braun M; Dietert G; Scherer P; Grandien K; Theilhaber J; Cao H; Wagenaar TR; Schnurr MM; Endres S; Wiederschain D; Scheidler S; Rothenfußer S; Brunner B; König LM
Mol Cancer Ther; 2019 Dec; 18(12):2343-2356. PubMed ID: 31515294
[TBL] [Abstract][Full Text] [Related]
12. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.
Landsberg J; Kohlmeyer J; Renn M; Bald T; Rogava M; Cron M; Fatho M; Lennerz V; Wölfel T; Hölzel M; Tüting T
Nature; 2012 Oct; 490(7420):412-6. PubMed ID: 23051752
[TBL] [Abstract][Full Text] [Related]
13. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
14. Innate RIG-I signaling restores antigen presentation in tumors and overcomes T cell resistance.
Thier B; Paschen A
Cell Stress; 2021 Jan; 5(2):26-28. PubMed ID: 33554047
[TBL] [Abstract][Full Text] [Related]
15. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
16. Evolution of melanoma cross-resistance to CD8
Pieper N; Zaremba A; Leonardelli S; Harbers FN; Schwamborn M; Lübcke S; Schrörs B; Baingo J; Schramm A; Haferkamp S; Seifert U; Sucker A; Lennerz V; Wölfel T; Schadendorf D; Schilling B; Paschen A; Zhao F
Oncoimmunology; 2018; 7(8):e1450127. PubMed ID: 30221038
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
Noguchi K; Dalton AC; Howley BV; McCall BJ; Yoshida A; Diehl JA; Howe PH
PLoS One; 2017; 12(5):e0177830. PubMed ID: 28545079
[TBL] [Abstract][Full Text] [Related]
18. CDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma.
Berico P; Cigrang M; Davidson G; Braun C; Sandoz J; Legras S; Vokshi BH; Slovic N; Peyresaubes F; Gene Robles CM; Egly JM; Compe E; Davidson I; Coin F
EMBO Rep; 2021 Sep; 22(9):e51683. PubMed ID: 34296805
[TBL] [Abstract][Full Text] [Related]
19. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.
Besch R; Poeck H; Hohenauer T; Senft D; Häcker G; Berking C; Hornung V; Endres S; Ruzicka T; Rothenfusser S; Hartmann G
J Clin Invest; 2009 Aug; 119(8):2399-411. PubMed ID: 19620789
[TBL] [Abstract][Full Text] [Related]
20. Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.
Zhao F; Sucker A; Horn S; Heeke C; Bielefeld N; Schrörs B; Bicker A; Lindemann M; Roesch A; Gaudernack G; Stiller M; Becker JC; Lennerz V; Wölfel T; Schadendorf D; Griewank K; Paschen A
Cancer Res; 2016 Aug; 76(15):4347-58. PubMed ID: 27261508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
